Allergy Therapeutics

We provide information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with a special focus on allergy vaccination (also known as specific immunotherapy or desensitisation therapy). Allergy vaccination is a successful treatment that deals with the underlying cause of allergies and not just the symptoms! Allergy Therapeutics has a long-term commitment to the development of innovative therapies for allergy treatment and allergy prevention.
Type
Public
HQ
Worthing, GB
Founded
1934
Employees
373 (est)
Allergy Therapeutics was founded in 1934 and is headquartered in Worthing, GB

Allergy Therapeutics Locations

Worthing, GB

Allergy Therapeutics Metrics

Allergy Therapeutics Summary

Market capitalization

£138 M

Closing share price

£0.23
Allergy Therapeutics's current market capitalization is £138 M.

Allergy Therapeutics Financials

We estimate that Allergy Therapeutics's revenue is £43.2 M in FY, 2015 which is 3.04% increase from the previous period.
FY, 2013FY, 2014FY, 2015

Revenue

£39.3 M£42 M£43.2 M

Revenue growth, %

6.8%3.0%

Cost of sales

£12 M£12 M£12.2 M

Gross profit

£27.3 M£30 M£31.1 M

Gross profit Margin, %

69.6%71.5%71.8%

Operating expense total

£26.7 M£28.8 M£30.3 M

    Allergy Therapeutics Market Value History

    Allergy Therapeutics News

    Allergy Therapeutics Company Life

    You may also be interested in